Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III gantenerumab in early Alzheimer's disease
jRCT2080223909Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab with Placebo (2 arms). Primary endpoint: Clinical Dementia Rating – Sum of Boxes (CDR-SB). Started May 2018; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223909.